Balance Sheet
Cash Flow Statement
AcquisitionsAmortizatization of IntangiblesAmortizatization of IntangiblesAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesChange in TaxesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesLong-Term Debt IssuancesLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesSales of Property, Plant and EquipmentSales of Property, Plant and EquipmentShare-based CompensationShare-based CompensationShares IssuedShares Repurchased
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Haemonetics (HAE) Share-based Compensation (2016 - 2025)

Haemonetics has reported Share-based Compensation over the past 17 years, most recently at $7.8 million for Q4 2025.

  • For Q4 2025, Share-based Compensation fell 5.05% year-over-year to $7.8 million; the TTM value through Dec 2025 reached $31.6 million, up 5.04%, while the annual FY2025 figure was $29.6 million, 4.6% up from the prior year.
  • Share-based Compensation for Q4 2025 was $7.8 million at Haemonetics, up from $7.6 million in the prior quarter.
  • Over five years, Share-based Compensation peaked at $9.3 million in Q2 2025 and troughed at $5.1 million in Q2 2022.
  • A 5-year average of $7.0 million and a median of $7.0 million in 2023 define the central range for Share-based Compensation.
  • Biggest five-year swings in Share-based Compensation: dropped 28.31% in 2022 and later surged 38.47% in 2023.
  • Year by year, Share-based Compensation stood at $6.0 million in 2021, then rose by 25.29% to $7.5 million in 2022, then fell by 3.66% to $7.2 million in 2023, then increased by 13.81% to $8.2 million in 2024, then decreased by 5.05% to $7.8 million in 2025.
  • Business Quant data shows Share-based Compensation for HAE at $7.8 million in Q4 2025, $7.6 million in Q3 2025, and $9.3 million in Q2 2025.